The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients

One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-03, Vol.14 (6), p.1569
Main Authors: Derebas, Justyna, Panuciak, Kinga, Margas, Mikołaj, Zawitkowska, Joanna, Lejman, Monika
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Blood diseases
Cancer therapies
Cell cycle
Cell therapy
Chemotherapy
Children
Chimeric antigen receptors
Cytotoxicity
Deoxyribonucleic acid
DNA
Drug dosages
FDA approval
Gene amplification
Hematological diseases
Immune system
Immunosuppressive agents
Immunotherapy
Lymphocytes T
Lymphoma
Medical prognosis
Monoclonal antibodies
Mortality
Non-Hodgkin's lymphoma
Patients
Pediatrics
Radiation
Review
Stem cell transplantation
T cell receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3
cites cdi_FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3
container_end_page
container_issue 6
container_start_page 1569
container_title Cancers
container_volume 14
creator Derebas, Justyna
Panuciak, Kinga
Margas, Mikołaj
Zawitkowska, Joanna
Lejman, Monika
description One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.
doi_str_mv 10.3390/cancers14061569
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8945992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2642355292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3</originalsourceid><addsrcrecordid>eNpdkU1LAzEQhoMoVqpnb7Lgxctqvre5CCJqhVo91HPIZiftandTk63Sf2-0VbRzmYF55p0ZXoSOCT5nTOELa1oLIRKOJRFS7aADiguaS6n47p-6h45ifMEpGCOFLPZRjwlGZUHUARpOZpCN4SObBDBdA22XPUA381XMnA_Z2Lf50FfT17rNRqtmMfONyVL9BFVtulDb7Ml0dZqKh2jPmXmEo03uo-fbm8n1MB893t1fX41yyynp8lIwV1JQlNFSiIoMmHOSYumYUJiX4KAymIIoRGkVSRBzA6oG1FhrhaTA-uhyrbtYlg1UNu0OZq4XoW5MWGlvav2_09YzPfXveqC4UGlvH51tBIJ_W0LsdFNHC_O5acEvo6aSc0wx5yShp1voi1-GNr33RVEmBP0WvFhTNvgYA7jfYwjWX0bpLaPSxMnfH375H1vYJ6Kkj5U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642355292</pqid></control><display><type>article</type><title>The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Derebas, Justyna ; Panuciak, Kinga ; Margas, Mikołaj ; Zawitkowska, Joanna ; Lejman, Monika</creator><creatorcontrib>Derebas, Justyna ; Panuciak, Kinga ; Margas, Mikołaj ; Zawitkowska, Joanna ; Lejman, Monika</creatorcontrib><description>One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14061569</identifier><identifier>PMID: 35326719</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Apoptosis ; Blood diseases ; Cancer therapies ; Cell cycle ; Cell therapy ; Chemotherapy ; Children ; Chimeric antigen receptors ; Cytotoxicity ; Deoxyribonucleic acid ; DNA ; Drug dosages ; FDA approval ; Gene amplification ; Hematological diseases ; Immune system ; Immunosuppressive agents ; Immunotherapy ; Lymphocytes T ; Lymphoma ; Medical prognosis ; Monoclonal antibodies ; Mortality ; Non-Hodgkin's lymphoma ; Patients ; Pediatrics ; Radiation ; Review ; Stem cell transplantation ; T cell receptors</subject><ispartof>Cancers, 2022-03, Vol.14 (6), p.1569</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3</citedby><cites>FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3</cites><orcidid>0000-0001-9014-5171 ; 0000-0002-7420-0190 ; 0000-0002-8760-0775 ; 0000-0001-7207-156X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2642355292/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2642355292?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35326719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Derebas, Justyna</creatorcontrib><creatorcontrib>Panuciak, Kinga</creatorcontrib><creatorcontrib>Margas, Mikołaj</creatorcontrib><creatorcontrib>Zawitkowska, Joanna</creatorcontrib><creatorcontrib>Lejman, Monika</creatorcontrib><title>The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.</description><subject>Antigens</subject><subject>Apoptosis</subject><subject>Blood diseases</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell therapy</subject><subject>Chemotherapy</subject><subject>Children</subject><subject>Chimeric antigen receptors</subject><subject>Cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Gene amplification</subject><subject>Hematological diseases</subject><subject>Immune system</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Radiation</subject><subject>Review</subject><subject>Stem cell transplantation</subject><subject>T cell receptors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU1LAzEQhoMoVqpnb7Lgxctqvre5CCJqhVo91HPIZiftandTk63Sf2-0VbRzmYF55p0ZXoSOCT5nTOELa1oLIRKOJRFS7aADiguaS6n47p-6h45ifMEpGCOFLPZRjwlGZUHUARpOZpCN4SObBDBdA22XPUA381XMnA_Z2Lf50FfT17rNRqtmMfONyVL9BFVtulDb7Ml0dZqKh2jPmXmEo03uo-fbm8n1MB893t1fX41yyynp8lIwV1JQlNFSiIoMmHOSYumYUJiX4KAymIIoRGkVSRBzA6oG1FhrhaTA-uhyrbtYlg1UNu0OZq4XoW5MWGlvav2_09YzPfXveqC4UGlvH51tBIJ_W0LsdFNHC_O5acEvo6aSc0wx5yShp1voi1-GNr33RVEmBP0WvFhTNvgYA7jfYwjWX0bpLaPSxMnfH375H1vYJ6Kkj5U</recordid><startdate>20220318</startdate><enddate>20220318</enddate><creator>Derebas, Justyna</creator><creator>Panuciak, Kinga</creator><creator>Margas, Mikołaj</creator><creator>Zawitkowska, Joanna</creator><creator>Lejman, Monika</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9014-5171</orcidid><orcidid>https://orcid.org/0000-0002-7420-0190</orcidid><orcidid>https://orcid.org/0000-0002-8760-0775</orcidid><orcidid>https://orcid.org/0000-0001-7207-156X</orcidid></search><sort><creationdate>20220318</creationdate><title>The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients</title><author>Derebas, Justyna ; Panuciak, Kinga ; Margas, Mikołaj ; Zawitkowska, Joanna ; Lejman, Monika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Apoptosis</topic><topic>Blood diseases</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell therapy</topic><topic>Chemotherapy</topic><topic>Children</topic><topic>Chimeric antigen receptors</topic><topic>Cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Gene amplification</topic><topic>Hematological diseases</topic><topic>Immune system</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Radiation</topic><topic>Review</topic><topic>Stem cell transplantation</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Derebas, Justyna</creatorcontrib><creatorcontrib>Panuciak, Kinga</creatorcontrib><creatorcontrib>Margas, Mikołaj</creatorcontrib><creatorcontrib>Zawitkowska, Joanna</creatorcontrib><creatorcontrib>Lejman, Monika</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Derebas, Justyna</au><au>Panuciak, Kinga</au><au>Margas, Mikołaj</au><au>Zawitkowska, Joanna</au><au>Lejman, Monika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-03-18</date><risdate>2022</risdate><volume>14</volume><issue>6</issue><spage>1569</spage><pages>1569-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35326719</pmid><doi>10.3390/cancers14061569</doi><orcidid>https://orcid.org/0000-0001-9014-5171</orcidid><orcidid>https://orcid.org/0000-0002-7420-0190</orcidid><orcidid>https://orcid.org/0000-0002-8760-0775</orcidid><orcidid>https://orcid.org/0000-0001-7207-156X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2022-03, Vol.14 (6), p.1569
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8945992
source Publicly Available Content (ProQuest); PubMed Central
subjects Antigens
Apoptosis
Blood diseases
Cancer therapies
Cell cycle
Cell therapy
Chemotherapy
Children
Chimeric antigen receptors
Cytotoxicity
Deoxyribonucleic acid
DNA
Drug dosages
FDA approval
Gene amplification
Hematological diseases
Immune system
Immunosuppressive agents
Immunotherapy
Lymphocytes T
Lymphoma
Medical prognosis
Monoclonal antibodies
Mortality
Non-Hodgkin's lymphoma
Patients
Pediatrics
Radiation
Review
Stem cell transplantation
T cell receptors
title The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A59%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20New%20Treatment%20Methods%20for%20Non-Hodgkin%20Lymphoma%20in%20Pediatric%20Patients&rft.jtitle=Cancers&rft.au=Derebas,%20Justyna&rft.date=2022-03-18&rft.volume=14&rft.issue=6&rft.spage=1569&rft.pages=1569-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14061569&rft_dat=%3Cproquest_pubme%3E2642355292%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-b53fb2e9232b55d183ff6206f35904befeda02e575bc9132b3f82982accc562e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2642355292&rft_id=info:pmid/35326719&rfr_iscdi=true